Evidence map›Paper›PMID 37434266›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.

Marianna Talia, Francesca Cirillo, Asia Spinelli, Azzurra Zicarelli, Domenica Scordamaglia, Lucia Muglia, Salvatore De Rosis, Damiano Cosimo Rigiracciolo, Gianfranco Filippelli, Ida Daniela Perrotta and 12 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Marianna Talia *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Francesca Cirillo *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Asia Spinelli *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Azzurra ZicarelliDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Domenica ScordamagliaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Lucia MugliaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Salvatore De RosisDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Damiano Cosimo RigiraccioloEuropean Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Gianfranco FilippelliOncology Department, Hospital of Paola, 87100, Cosenza, Italy.
Ida Daniela PerrottaDepartment of Biology, Ecology and Earth Science, University of Calabria, 87036, Rende, Italy.
Mariano DavoliDepartment of Biology, Ecology and Earth Science, University of Calabria, 87036, Rende, Italy.
Rosanna De RosaDepartment of Biology, Ecology and Earth Science, University of Calabria, 87036, Rende, Italy.
Rachele MacirellaDepartment of Biology, Ecology and Earth Science, University of Calabria, 87036, Rende, Italy.
Elvira BrunelliDepartment of Biology, Ecology and Earth Science, University of Calabria, 87036, Rende, Italy.
Anna Maria MigliettaBreast and General Surgery Unit, Regional Hospital Cosenza, 87100, Cosenza, Italy.
Bruno NardoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Daniela TosoniEuropean Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Salvatore PeceEuropean Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Ernestina Marianna De FrancescoEndocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, 95122, Italy.
Antonino BelfioreEndocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, 95122, Italy.
Marcello MaggioliniDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy. marcello.maggiolini@unical.it.
Rosamaria LappanoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy. rosamaria.lappano@unical.it.
University of Calabria · ITAzienda Ospedaliera di Cosenza · ITRipamonti · ITUniversity of Catania · ITUniversity of Milan · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 11904Associazione Italiana per la Ricerca sul Cancro 15538Associazione Italiana per la Ricerca sul Cancro 21322Associazione Italiana per la Ricerca sul Cancro 21651Associazione Italiana per la Ricerca sul Cancro 23369Associazione Italiana per la Ricerca sul Cancro 27386Ministero della Salute RF-2013-02358446Ministero della Salute RF-2019-12368937
6 · The paper itself

Abstract

backgroundThe receptor for advanced glycation-end products (RAGE) and its ligands have been implicated in obesity and associated inflammatory processes as well as in metabolic alterations like diabetes. In addition, RAGE-mediated signaling has been reported to contribute to the metastatic progression of breast cancer (BC), although mechanistic insights are still required. Here, we provide novel findings regarding the transcriptomic landscape and the molecular events through which RAGE may prompt aggressive features in estrogen receptor (ER)-positive BC.

methodsMCF7 and T47D BC cells stably overexpressing human RAGE were used as a model system to evaluate important changes like cell protrusions, migration, invasion and colony formation both in vitro through scanning electron microscopy, clonogenic, migration and invasion assays and in vivo through zebrafish xenografts experiments. The whole transcriptome of RAGE-overexpressing BC cells was screened by high-throughput RNA sequencing. Thereafter, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses allowed the prediction of potential functions of differentially expressed genes (DEGs). Flow cytometry, real time-PCR, chromatin immunoprecipitation, immunofluorescence and western blot assays were performed to investigate the molecular network involved in the regulation of a novel RAGE target gene namely EphA3. The clinical significance of EphA3 was explored in the TCGA cohort of patients through the survivALL package, whereas the pro-migratory role of EphA3 signaling was ascertained in both BC cells and cancer-associated fibroblasts (CAFs). Statistical analysis was performed by t-tests.

resultsRNA-seq findings and GSEA analysis revealed that RAGE overexpression leads to a motility-related gene signature in ER-positive BC cells. Accordingly, we found that RAGE-overexpressing BC cells exhibit long filopodia-like membrane protrusions as well as an enhanced dissemination potential, as determined by the diverse experimental assays. Mechanistically, we established for the first time that EphA3 signaling may act as a physical mediator of BC cells and CAFs motility through both homotypic and heterotypic interactions.

conclusionsOur data demonstrate that RAGE up-regulation leads to migratory ability in ER-positive BC cells. Noteworthy, our findings suggest that EphA3 may be considered as a novel RAGE target gene facilitating BC invasion and scattering from the primary tumor mass. Overall, the current results may provide useful insights for more comprehensive therapeutic approaches in BC, particularly in obese and diabetic patients that are characterized by high RAGE levels.

Indexed as

Breast NeoplasmsReceptor, EphA3Receptor for Advanced Glycation End ProductsAnimalsFemaleHumansSignal TransductionZebrafishAGER protein, humanEPHA3 protein, humanReceptor, EphA3Receptor for Advanced Glycation End ProductsBreast cancerCancer-associated fibroblast (CAFs)EphA3Receptor for advanced glycation end-products (RAGE)

Identifiers

PMID37434266
PMCPMC10337103
OpenAlexW4383999289

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.